Researchers at Karolinska Institutet have developed a method that should be able to predict whether a patient with breast cancer will benefit from a particular treatment or not. The cell-based method has been tested on patients ...
Dec 27, 2022
0
106
For many breast cancer patients, the road to recovery may present hidden complications related to breast reconstruction following a mastectomy.
Dec 23, 2022
0
87
Researchers at Indiana University School of Medicine are learning more about ways to prevent serious side effects from chemotherapy used to treat breast cancer patients. The work done by the Schneider lab at the Vera Bradley ...
Dec 20, 2022
0
68
Cambridge scientists have managed to identify and kill those breast cancer cells that evade standard treatments in a study in mice. The approach is a step towards the development of new treatments to prevent relapse in patients.
Dec 20, 2022
0
14
Researchers at Memorial Sloan Kettering Cancer Center (MSKCC) in New York have discovered that common cancer treatments, such as radiotherapy or anthracycline drugs, cause long-term damage to heart tissue by activating a ...
Dec 19, 2022
0
6
For patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-negative early breast cancer (EBC) with a 21-gene recurrence score (RS) of 11 to 25, adjuvant endocrine therapy ...
Dec 12, 2022
0
2
Patients with multiple tumors in the same breast who underwent a lumpectomy followed by radiation therapy had local recurrence rates comparable to those historically observed in patients with a single tumor, according to ...
Dec 9, 2022
0
2
Breast cancer patients who paused their endocrine therapy to try to get pregnant experienced short-term rates of breast cancer recurrence similar to women who did not pause therapy for pregnancy, and many went on to conceive ...
Dec 9, 2022
0
5
Patients with localized, hormone receptor-positive, HER2-low breast cancer treated with trastuzumab deruxtecan (T-DXd, Enhertu) in the neoadjuvant setting had an overall response rate of 75 percent in the absence of anastrozole ...
Dec 7, 2022
0
2
In patients with hormone receptor-positive, HER2-negative, advanced breast cancer—including patients with visceral crises—those treated with ribociclib plus endocrine therapy had fewer adverse events and a significantly ...
Dec 6, 2022
0
3
